Noga Askenazi, MD
Allergy & Immunology · Crystal Lake, ILNPI 1972518702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 529 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations.
Across 529 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$2K
- CSL Behring$1K
- GSK$937
- Regeneron Healthcare Solutions, Inc.$863
- Takeda Pharmaceuticals U.S.A., Inc.$682
- plus $5K from 33 others
What the payments were for
- Food & beverage$11,63898%
- Education$2912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $2,182 |
| Sanofi | 64 | $1,531 |
| CSL Behring | 35 | $1,013 |
| GSK | 60 | $937 |
| Regeneron Healthcare Solutions, Inc. | 35 | $863 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $682 |
| Pfizer | 25 | $450 |
| Genentech USA, Inc. | 27 | $378 |
| Blueprint Medicines Corporation | 8 | $358 |
| Octapharma USA, Inc. | 5 | $285 |
| Shire North American Group Inc | 14 | $268 |
| Teva Pharmaceuticals USA, Inc. | 16 | $264 |
| Grifols USA, LLC | 11 | $264 |
| Boehringer Ingelheim | 12 | $252 |
| Hospira, Inc. | 9 | $218 |
| Covis Pharma GmbH | 10 | $216 |
| Pharming Healthcare, Inc. | 9 | $205 |
| Kaleo, Inc. | 11 | $191 |
| Merck | 2 | $174 |
| Alk-abello, Inc | 7 | $162 |
| Optinose US, Inc. | 10 | $153 |
| Sanofi-aventis U.S. LLC | 2 | $147 |
| Biocryst US Sales Co., LLC | 7 | $140 |
| Amgen | 5 | $120 |
| Novartis | 5 | $101 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| Phadia US Inc. | 3 | $52 |
| AbbVie | 2 | $49 |
| Circassia Inc. | 1 | $30 |
| Biocryst Pharmaceuticals, Inc. | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Arcutis Biotherapeutics, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Bio Products Laboratory USA, Inc. | 1 | $18 |
| GC Biopharma USA, Inc. | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| QOL Medical, LLC | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,929 in reported general payments places this provider in the 80th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 72 | $282,317 |
| Breo ElliptaFluticasone/Vilanterol | 79 | $64,684 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $19,120 |
| Arnuity ElliptaFluticasone Furoate | 27 | $11,241 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $10,085 |
| Advair HfaFluticasone Propion/Salmeterol | 25 | $9,537 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $8,638 |
| Epinephrine | 30 | $5,355 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $5,238 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $3,354 |
| Montelukast Sodium | 291 | $3,293 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,433 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $1,922 |
| Levocetirizine Dihydrochloride | 58 | $1,673 |
| Azelastine Hcl | 57 | $1,217 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $937 | $95,045117 claims |
| AstraZenecaSymbicort | $2,182 | $8,63826 claims |
| Hikma Pharmaceuticals USAEpinephrine | $16 | $5,35530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Crystal Lake
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.